Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
VVOS logo VVOS
Upturn stock ratingUpturn stock rating
VVOS logo

Vivos Therapeutics Inc (VVOS)

Upturn stock ratingUpturn stock rating
$4.61
Last Close (24-hour delay)
Profit since last BUY40.55%
upturn advisory
WEAK BUY
BUY since 34 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: VVOS (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4.22

1 Year Target Price $4.22

Analysts Price Target For last 52 week
$4.22 Target price
52w Low $1.98
Current$4.61
52w High $7.95

Analysis of Past Performance

Type Stock
Historic Profit -6.65%
Avg. Invested days 24
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 27.15M USD
Price to earnings Ratio -
1Y Target Price 4.22
Price to earnings Ratio -
1Y Target Price 4.22
Volume (30-day avg) 2
Beta 7
52 Weeks Range 1.98 - 7.95
Updated Date 08/15/2025
52 Weeks Range 1.98 - 7.95
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.04

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2025-08-15
When -
Estimate -0.385
Actual -

Profitability

Profit Margin -76.82%
Operating Margin (TTM) -129.91%

Management Effectiveness

Return on Assets (TTM) -61.21%
Return on Equity (TTM) -450.47%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 26207687
Price to Sales(TTM) 1.86
Enterprise Value 26207687
Price to Sales(TTM) 1.86
Enterprise Value to Revenue 1.79
Enterprise Value to EBITDA -0.21
Shares Outstanding 5889520
Shares Floating 3818883
Shares Outstanding 5889520
Shares Floating 3818883
Percent Insiders 32.99
Percent Institutions 8.93

ai summary icon Upturn AI SWOT

Vivos Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Vivos Therapeutics, Inc. was founded in 2016. It focuses on developing and commercializing innovative technologies and protocols for treating mild-to-moderate obstructive sleep apnea (OSA) and sleep-disordered breathing in adults and children.

business area logo Core Business Areas

  • Medical Devices: Development and sale of the Vivos System, a non-surgical, non-pharmaceutical treatment modality for OSA and sleep-disordered breathing, including the DNA appliance and mRNA appliance.
  • Educational Programs: Providing training and certification programs for dentists to become Vivos-integrated practitioners, enabling them to offer Vivos treatment to their patients.

leadership logo Leadership and Structure

Kirk Huntsman is the CEO. The company has a board of directors and an executive team overseeing different departments, including sales, marketing, research & development, and clinical operations.

Top Products and Market Share

overview logo Key Offerings

  • DNA Appliance: A removable oral appliance designed to expand the upper airway, aiming to correct the underlying causes of OSA. Market share data is not publicly available. Competitors: Align Technology (Invisalign) in the broader orthodontic market, but few directly address OSA in the same way. Some overlap with mandibular advancement devices.
  • mRNA Appliance: Another removable oral appliance that works similarly to the DNA appliance but is designed for a broader range of patients. Market share data is not publicly available. Competitors: Align Technology (Invisalign), mandibular advancement devices, CPAP machines (ResMed, Philips).
  • Vivos Integrated Practice (VIP) program: Educational program to train dentists on the Vivos Method. Number of enrolled practices not public. Competitors: Various continuing education providers in dentistry.

Market Dynamics

industry overview logo Industry Overview

The market for OSA treatment is large and growing, driven by increasing awareness, aging populations, and rising obesity rates. Current treatments include CPAP, oral appliances, and surgery.

Positioning

Vivos positions itself as offering a unique, non-surgical, potentially curative approach to OSA, differentiating itself from traditional symptomatic treatments like CPAP. They focus on addressing the underlying anatomical issues contributing to sleep apnea.

Total Addressable Market (TAM)

The global sleep apnea devices market is estimated at billions of dollars annually. Vivos is positioned to capture a segment of this market by providing a potentially curative therapy.

Upturn SWOT Analysis

Strengths

  • Non-surgical, potentially curative treatment for OSA
  • Focus on addressing the root cause of OSA
  • Proprietary technology and intellectual property
  • Growing network of Vivos-trained dentists
  • Alternative option to CPAP therapy

Weaknesses

  • Limited clinical data compared to established treatments like CPAP
  • Reliance on dentist adoption and training
  • Higher initial cost compared to some other treatments
  • Relatively small company with limited resources
  • Dependent on insurance coverage for reimbursement.

Opportunities

  • Expanding the network of Vivos-trained dentists
  • Increasing awareness among patients and physicians
  • Securing insurance coverage for Vivos treatment
  • Developing new products and applications for Vivos technology
  • Partnering with sleep clinics and other healthcare providers.

Threats

  • Competition from established OSA treatments (CPAP, surgery)
  • Lack of clinical data supporting the long-term efficacy of Vivos treatment
  • Changes in insurance reimbursement policies
  • Economic downturn affecting patient affordability
  • Regulatory hurdles

Competitors and Market Share

competitor logo Key Competitors

  • RMD
  • PRGO

Competitive Landscape

Vivos offers a unique approach that addresses root causes, differentiating it from symptom management. However, it faces significant competition from established players with greater resources and more extensive clinical data.

Growth Trajectory and Initiatives

Historical Growth: Requires analysis of historical financial data. Look for revenue growth trends and key drivers of growth.

Future Projections: Future growth projections are typically based on analyst estimates, which are not available here. However, growth will depend on factors such as adoption by dentists, insurance coverage, and new product development.

Recent Initiatives: Recent Initiatives includes new marketing and education campaigns to increase awareness and dentist adoption.

Summary

Vivos Therapeutics has a novel approach to treating sleep apnea with potential for long-term correction, which differentiates them. Adoption depends on educating dentists and securing insurance coverage, which is a challenge. Competition with giants and limited clinical data are major risks, but successful expansion could yield significant growth. Overall, Vivos is a company with high risk and high potential reward.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Third-party industry reports (where available)
  • Analyst reports (where available)

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Data may be limited or incomplete due to access restrictions. Market share estimates are approximate and based on publicly available information.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Vivos Therapeutics Inc

Exchange NASDAQ
Headquaters Littleton, CO, United States
IPO Launch date 2020-12-11
Co-Founder, Chairman of the Board & CEO Mr. R. Kirk Huntsman
Sector Healthcare
Industry Medical Devices
Full time employees 113
Full time employees 113

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.